Literature DB >> 28888662

Candida auris: An emerging multidrug-resistant pathogen.

David Sears1, Brian S Schwartz2.   

Abstract

Candida aurisis an emerging multidrug-resistant pathogen that can be difficult to identify using traditional biochemical methods. C. auris is capable of causing invasive fungal infections, particularly among hospitalized patients with significant medical comorbidities. Echinocandins are the empiric drugs of choice for C. auris, although not all isolates are susceptible and resistance may develop on therapy. Nosocomial C. auris outbreaks have been reported in a number of countries and aggressive infection control measures are paramount to stopping transmission.
Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Candida auris; Healthcare-associated; Infection control; Multidrug-resistance; Outbreak

Mesh:

Substances:

Year:  2017        PMID: 28888662     DOI: 10.1016/j.ijid.2017.08.017

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  40 in total

1.  Activity of anti-CR3-RP polyclonal antibody against biofilms formed by Candida auris, a multidrug-resistant emerging fungal pathogen.

Authors:  Jaroslava Dekkerová; Jose L Lopez-Ribot; Helena Bujdáková
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-10-16       Impact factor: 3.267

Review 2.  Targeting the alternative oxidase (AOX) for human health and food security, a pharmaceutical and agrochemical target or a rescue mechanism?

Authors:  Marten Szibor; Christina Schenkl; Mario R O Barsottini; Luke Young; Anthony L Moore
Journal:  Biochem J       Date:  2022-06-30       Impact factor: 3.766

Review 3.  New strategies for combating fungal infections: Inhibiting inositol lipid signaling by targeting Sec14 phosphatidylinositol transfer proteins.

Authors:  Vytas A Bankaitis; Ashutosh Tripathi; Xiao-Ru Chen; Tatyana I Igumenova
Journal:  Adv Biol Regul       Date:  2022-02-25

4.  Inhibition of Candida auris Biofilm Formation on Medical and Environmental Surfaces by Silver Nanoparticles.

Authors:  Humberto H Lara; Liliana Ixtepan-Turrent; Miguel Jose Yacaman; Jose Lopez-Ribot
Journal:  ACS Appl Mater Interfaces       Date:  2020-01-16       Impact factor: 9.229

Review 5.  Targeting intrinsic cell death pathways to control fungal pathogens.

Authors:  Madhura Kulkarni; Zachary D Stolp; J Marie Hardwick
Journal:  Biochem Pharmacol       Date:  2019-01-17       Impact factor: 5.858

6.  Recognition of Diagnostic Gaps for Laboratory Diagnosis of Fungal Diseases: Expert Opinion from the Fungal Diagnostics Laboratories Consortium (FDLC).

Authors:  Sean X Zhang; N Esther Babady; Kimberly E Hanson; Amanda T Harrington; Paige M K Larkin; Sixto M Leal; Paul M Luethy; Isabella W Martin; Preeti Pancholi; Gary W Procop; Stefan Riedel; Seyedmojtaba Seyedmousavi; Kaede V Sullivan; Thomas J Walsh; Shawn R Lockhart
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

Review 7.  Regulation of C-Type Lectin Receptor-Mediated Antifungal Immunity.

Authors:  Juan Tang; Guoxin Lin; Wallace Y Langdon; Lijian Tao; Jian Zhang
Journal:  Front Immunol       Date:  2018-02-01       Impact factor: 7.561

8.  Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development.

Authors:  Gina Wall; Ashok K Chaturvedi; Floyd L Wormley; Nathan P Wiederhold; Hoja P Patterson; Thomas F Patterson; José L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 9.  Microbial Air Quality in Healthcare Facilities.

Authors:  Lucia Bonadonna; Rossella Briancesco; Anna Maria Coccia; Pierluigi Meloni; Giuseppina La Rosa; Umberto Moscato
Journal:  Int J Environ Res Public Health       Date:  2021-06-09       Impact factor: 3.390

10.  HECT E3 Ubiquitin Ligase Nedd4 Is Required for Antifungal Innate Immunity.

Authors:  Patrick K Nuro-Gyina; Na Tang; Hui Guo; Chengkai Yan; Qiuming Zeng; Thomas J Waldschmidt; Jian Zhang
Journal:  J Immunol       Date:  2021-07-19       Impact factor: 5.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.